Isabel Rauscher1, Thomas Horn2, Matthias Eiber3, Jürgen E Gschwend2, Tobias Maurer2. 1. Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany. isabel.rauscher@tum.de. 2. Department of Urology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany. 3. Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany.
Abstract
PURPOSE: Recently, prostate-specific membrane antigen-radioguided surgery (PSMA-RGS) has been introduced as a promising new and individual treatment concept in patients with localised recurrent prostate cancer (PC). In the following, we want to review our experience with PSMA-RGS in patients with localised biochemical recurrent PC. METHODS: A non-systematic review of the literature was carried out with focus on technical and logistical aspects of PSMA-RGS. Furthermore, published data on intraoperative detection of metastatic lesions compared to preoperative PSMA-PET and postoperative histopathology, postoperative complications as well as oncological follow-up data are summarized. Finally, relevant aspects on prerequisites for PSMA-RGS, patient selection, and the potential benefit of additional salvage radiotherapy or potential future applications of robotic PSMA-RGS with drop-in γ-probes are discussed. RESULTS: First results show that PSMA-RGS is very sensitive and specific in tracking suspicious lesions intraoperatively. Prerequisite for patient selection and localisation of tumour recurrence is a positive Ga-HBED-CC PSMA positron-emission tomography (PET) scan with preferably only singular soft tissue or lymph node recurrence after primary treatment. Furthermore, PSMA-RGS has the potential to positively influence oncological outcome. CONCLUSIONS: PSMA-RGS seems to be of high value in patients with localised PC recurrence for exact localisation and resection of oftentimes small metastatic lesions using intraoperative and ex vivo γ-probe measurements. However, patient identification on the basis of Ga-HBED-CC-PSMA PET imaging as well as clinical parameters is crucial to obtain satisfactory results.
PURPOSE: Recently, prostate-specific membrane antigen-radioguided surgery (PSMA-RGS) has been introduced as a promising new and individual treatment concept in patients with localised recurrent prostate cancer (PC). In the following, we want to review our experience with PSMA-RGS in patients with localised biochemical recurrent PC. METHODS: A non-systematic review of the literature was carried out with focus on technical and logistical aspects of PSMA-RGS. Furthermore, published data on intraoperative detection of metastatic lesions compared to preoperative PSMA-PET and postoperative histopathology, postoperative complications as well as oncological follow-up data are summarized. Finally, relevant aspects on prerequisites for PSMA-RGS, patient selection, and the potential benefit of additional salvage radiotherapy or potential future applications of robotic PSMA-RGS with drop-in γ-probes are discussed. RESULTS: First results show that PSMA-RGS is very sensitive and specific in tracking suspicious lesions intraoperatively. Prerequisite for patient selection and localisation of tumour recurrence is a positive Ga-HBED-CC PSMA positron-emission tomography (PET) scan with preferably only singular soft tissue or lymph node recurrence after primary treatment. Furthermore, PSMA-RGS has the potential to positively influence oncological outcome. CONCLUSIONS:PSMA-RGS seems to be of high value in patients with localised PC recurrence for exact localisation and resection of oftentimes small metastatic lesions using intraoperative and ex vivo γ-probe measurements. However, patient identification on the basis of Ga-HBED-CC-PSMA PET imaging as well as clinical parameters is crucial to obtain satisfactory results.
Entities:
Keywords:
Oligometastatic; PSA; PSMA; Prostate cancer; Radioguided surgery; Salvage surgery
Authors: Matthias N van Oosterom; Hervé Simon; Laurent Mengus; Mick M Welling; Henk G van der Poel; Nynke S van den Berg; Fijs Wb van Leeuwen Journal: Am J Nucl Med Mol Imaging Date: 2016-01-28
Authors: Isabel Rauscher; Charlotte Düwel; Martina Wirtz; Margret Schottelius; Hans-Jürgen Wester; Kristina Schwamborn; Bernhard Haller; Markus Schwaiger; Jürgen E Gschwend; Matthias Eiber; Tobias Maurer Journal: BJU Int Date: 2016-12-04 Impact factor: 5.588
Authors: Ken Herrmann; Christina Bluemel; Martina Weineisen; Margret Schottelius; Hans-Jürgen Wester; Johannes Czernin; Uta Eberlein; Seval Beykan; Constantin Lapa; Hubertus Riedmiller; Markus Krebs; Saskia Kropf; Andreas Schirbel; Andreas K Buck; Michael Lassmann Journal: J Nucl Med Date: 2015-04-16 Impact factor: 10.057
Authors: Greta Meredith; David Wong; John Yaxley; Geoff Coughlin; Les Thompson; Boon Kua; Troy Gianduzzo Journal: BJU Int Date: 2016-09-23 Impact factor: 5.588
Authors: C A Jilg; H C Rischke; S N Reske; K Henne; A-L Grosu; W Weber; V Drendel; M Schwardt; A Jandausch; W Schultze-Seemann Journal: J Urol Date: 2012-10-18 Impact factor: 7.450
Authors: Tobias Maurer; Gregor Weirich; Margret Schottelius; Martina Weineisen; Benjamin Frisch; Asli Okur; Hubert Kübler; Mark Thalgott; Nassir Navab; Markus Schwaiger; Hans-Jürgen Wester; Jürgen E Gschwend; Matthias Eiber Journal: Eur Urol Date: 2015-05-06 Impact factor: 20.096
Authors: Martina Weineisen; Jakub Simecek; Margret Schottelius; Markus Schwaiger; Hans-Jürgen Wester Journal: EJNMMI Res Date: 2014-11-25 Impact factor: 3.138
Authors: Michael Mix; Kathrin Reichel; Christian Stoykow; Mark Bartholomä; Vanessa Drendel; Eleni Gourni; Ulrich Wetterauer; Wolfgang Schultze-Seemann; Philipp T Meyer; Cordula A Jilg Journal: Eur J Nucl Med Mol Imaging Date: 2018-07-30 Impact factor: 9.236
Authors: E M Kwan; I A Thangasamy; J Teh; O Alghazo; N J Sathianathen; N Lawrentschuk; A A Azad Journal: World J Urol Date: 2020-01-02 Impact factor: 4.226
Authors: Margret Schottelius; Alexander Wurzer; Katharina Wissmiller; Roswitha Beck; Maximilian Koch; Dimitrios Gorpas; Johannes Notni; Tessa Buckle; Matthias N van Oosterom; Katja Steiger; Vasilis Ntziachristos; Markus Schwaiger; Fijs W B van Leeuwen; Hans-Jürgen Wester Journal: J Nucl Med Date: 2018-09-20 Impact factor: 10.057
Authors: Yvonne H W Derks; Dennis W P M Löwik; J P Michiel Sedelaar; Martin Gotthardt; Otto C Boerman; Mark Rijpkema; Susanne Lütje; Sandra Heskamp Journal: Theranostics Date: 2019-09-20 Impact factor: 11.556
Authors: Thomas Wendler; Fijs W B van Leeuwen; Nassir Navab; Matthias N van Oosterom Journal: Eur J Nucl Med Mol Imaging Date: 2021-06-29 Impact factor: 9.236